Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Serena Rocchi"'
Autor:
Giovanni Marconi, Michela Rondoni, Beatrice Anna Zannetti, Irene Zacheo, Davide Nappi, Agnese Mattei, Serena Rocchi, Francesco Lanza
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Secondary acute myeloid leukemia (sAML) presents as a complex and multifaceted ensemble of disorders, positioning itself as both a challenge and an intriguing frontier within hematologic oncology. Its origins are diverse, stemming from antecedent hem
Externí odkaz:
https://doaj.org/article/954a71334d52491db9deccc491c528e8
Autor:
Carolina Terragna, Andrea Poletti, Vincenza Solli, Marina Martello, Elena Zamagni, Lucia Pantani, Enrica Borsi, Ilaria Vigliotta, Gaia Mazzocchetti, Silvia Armuzzi, Barbara Taurisano, Nicoletta Testoni, Giulia Marzocchi, Ajsi Kanapari, Ignazia Pistis, Paola Tacchetti, Katia Mancuso, Serena Rocchi, Ilaria Rizzello, Michele Cavo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract The complexity of Multiple Myeloma (MM) is driven by several genomic aberrations, interacting with disease-related and/or -unrelated factors and conditioning patients’ clinical outcome. Patient’s prognosis is hardly predictable, as commo
Externí odkaz:
https://doaj.org/article/b0670f38bd1042f68b22b11a9e85ac10
Autor:
Flavia Bigi, Paola Tacchetti, Alessandro Giorgi, Gaia Mazzocchetti, Vincenza Solli, Simona Barbato, Barbara Sinigaglia, Elena Campanini, Emanuele Favero, Marco Talarico, Michele Puppi, Ilaria Rizzello, Serena Rocchi, Katia Mancuso, Lucia Pantani, Michele Cavo, Elena Zamagni
Publikováno v:
Frontiers in Hematology, Vol 3 (2024)
The impact of daratumumab on CD34+ hematopoietic stem cell (HSC) mobilization has recently been a matter of concern. To address this issue, we compared CD34+ HSC-related outcomes in patients with multiple myeloma treated with daratumumab-based quadru
Externí odkaz:
https://doaj.org/article/950b5b65be544c078de9b75b3a23a37d
Autor:
Claudia Ielo, Francesca Fazio, Serena Rocchi, Ilaria Rizzello, Katia Mancuso, Elena Zamagni, Michele Cavo, Maria Teresa Petrucci
Publikováno v:
Leukemia Research Reports, Vol 21, Iss , Pp 100399- (2024)
Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, immune impairment induced by cellular therapies, previous treatments and MM itself could promote in
Externí odkaz:
https://doaj.org/article/4f56c4373408401caaebb82a8e019d26
Publikováno v:
Cells, Vol 13, Iss 10, p 853 (2024)
Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell transplantation (ASCT) has established itself as a core treatment for newly diagnosed multiple myeloma (NDMM) patients in the past 30 years. Induction therapy, HDM-ASCT,
Externí odkaz:
https://doaj.org/article/6e3cf697b3ac4e92afcf91bc71db9397
Autor:
Enrica Borsi, Ilaria Vigliotta, Andrea Poletti, Gaia Mazzocchetti, Vincenza Solli, Luca Zazzeroni, Marina Martello, Silvia Armuzzi, Barbara Taurisano, Ajsi Kanapari, Ignazia Pistis, Elena Zamagni, Lucia Pantani, Serena Rocchi, Katia Mancuso, Paola Tacchetti, Ilaria Rizzello, Simonetta Rizzi, Elisa Dan, Barbara Sinigaglia, Michele Cavo, Carolina Terragna
Publikováno v:
Cells, Vol 13, Iss 8, p 657 (2024)
Clonal hematopoiesis of indeterminate potential (CHIP) refers to the phenomenon where a hematopoietic stem cell acquires fitness-increasing mutation(s), resulting in its clonal expansion. CHIP is frequently observed in multiple myeloma (MM) patients,
Externí odkaz:
https://doaj.org/article/9eb6935ac05845519040d5dd9482e687
Autor:
Francesco Autore, Stefania Bramanti, Federica Lessi, Idanna Innocenti, Eugenio Galli, Serena Rocchi, Rossella Ribolla, Daniele Derudas, Stefania Oliva, Paola Stefanoni, Magda Marcatti, Angelo Schenone, Giorgio La Nasa, Claudia Crippa, Elena Zamagni, Marcello Riva, Rita Mazza, Daniele Mannina, Simona Sica, Andrea Bacigalupo, Luca Laurenti
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Autologous peripheral blood stem cell transplantation (aPBSCT) provides optimal outcomes in POEMS syndrome but the definition of the best treatment before aPBSCT remains to be defined because of the rarity of the disease and the heterogeneity of publ
Externí odkaz:
https://doaj.org/article/49923cb4e2704333b3669372233d26c3
Autor:
Katia Mancuso, Elena Zamagni, Vincenza Solli, Liliana Gabrielli, Marta Leone, Lucia Pantani, Serena Rocchi, Ilaria Rizzello, Paola Tacchetti, Stefano Ghibellini, Emanuele Favero, Margherita Ursi, Marco Talarico, Simona Barbato, Ajsi Kanapari, Flavia Bigi, Michele Puppi, Carolina Terragna, Enrica Borsi, Marina Martello, Andrea Poletti, Alessandra Scatà, Giuliana Nepoti, Barbara Ruffini, Tiziana Lazzarotto, Michele Cavo
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Long-term kinetics of antibody (Ab) and cell-mediated immune (CMI) response to full anti-SARS-CoV-2 vaccine schedule and booster doses in Multiple Myeloma (MM) patients remain unclear. We prospectively evaluated Ab and CMI response to mRNA vaccines i
Externí odkaz:
https://doaj.org/article/6db24e4256444d06bdb7d131755a0f29
Autor:
Ilaria Vigliotta, Silvia Armuzzi, Martina Barone, Vincenza Solli, Ignazia Pistis, Enrica Borsi, Barbara Taurisano, Gaia Mazzocchetti, Marina Martello, Andrea Poletti, Chiara Sartor, Ilaria Rizzello, Lucia Pantani, Paola Tacchetti, Cristina Papayannidis, Katia Mancuso, Serena Rocchi, Elena Zamagni, Antonio Curti, Mario Arpinati, Michele Cavo, Carolina Terragna
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionMinimal residual disease (MRD) is commonly assessed in bone marrow (BM) aspirate. However, sample quality can impair the MRD measurement, leading to underestimated residual cells and to false negative results. To define a reliable and rep
Externí odkaz:
https://doaj.org/article/45f876f6faa8455682afb6ec6aa42bb9
Autor:
Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Enrico Iaccino, Selena Mimmi, Paola Curci, Barbara Gamberi, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Antonino Neri, Massimo Gentile
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidom
Externí odkaz:
https://doaj.org/article/558f55d38b4c4a8a985194fbba17f62d